Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates

Impact · against what's priced in

The partnership expands Teva's biosimilar pipeline with two confirmed and four potential candidates, but the lack of available price reconstructions prevents a determination of whether this is already priced in. The impact is potentially positive for long-term revenue but cannot be quantified against current market assumptions.

TEVA+0.00

No priced-in read yet